Antiobesity pharmacotherapy: new drugs and emerging targets.
Publication/Presentation Date
1-1-2014
Abstract
Obesity is a growing pandemic, and related health and economic costs are staggering. Pharmacotherapy, partnered with lifestyle modifications, forms the core of current strategies to reduce the burden of this disease and its sequelae. However, therapies targeting weight loss have a significant history of safety risks, including cardiovascular and psychiatric events. Here, evolving strategies for developing antiobesity therapies, including targets, mechanisms, and developmental status, are highlighted. Progress in this field is underscored by Belviq (lorcaserin) and Qsymia (phentermine/topiramate), the first agents in more than 10 years to achieve regulatory approval for chronic weight management in obese patients. On the horizon, novel insights into metabolism and energy homeostasis reveal guanosine 3',5'-cyclic monophosphate (cGMP) signaling circuits as emerging targets for antiobesity pharmacotherapy. These innovations in molecular discovery may elegantly align with practical off-the-shelf approaches, leveraging existing approved drugs that modulate cGMP levels for the management of obesity.
Volume
95
Issue
1
First Page
53
Last Page
66
ISSN
1532-6535
Published In/Presented At
Kim, G. W., Lin, J. E., Blomain, E. S., & Waldman, S. A. (2014). Antiobesity pharmacotherapy: new drugs and emerging targets. Clinical pharmacology and therapeutics, 95(1), 53–66. https://doi.org/10.1038/clpt.2013.204
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
24105257
Department(s)
Administration and Leadership
Document Type
Article